Alzheimer's disease (AD) affects more than 35 million people worldwide, and the number is
estimated to quadruple in 40 years if there remains no cure. 1–4 AD is characterized by the …

Alzheimer's disease (AD) is the leading cause of dementia, accounting for 60–70% of all
cases [Hebert et al., 2003, 1]. The need for effective therapies for AD is great. Current …

Preclinical diagnosis of Alzheimer's disease (AD) is one of the major challenges for the
prevention of AD. AD biomarkers are needed not only to reveal preclinical pathologic …

Alzheimer disease (AD) is the most common cause of dementia, accounting for 50% to 60%
of cases and affecting nearly 6 million people in the United States. The prevalence is …

Alzheimer's disease is defined neuropathologically by abnormal extra-cellular β-amyloid
plaques combined with intraneuronal tau aggregation (neurofibrillary tangles). Observations …

The different molecular paths that PET in-vivo biomarkers can reveal in the timeframe of
Alzheimer's disease progression reflect the events leading to deposition of Aβ and …

Alzheimer's disease (AD) is a major public health problem affecting nearly 35 million people
worldwide with numbers projected to rise to 115.4 million by 2050. Medicare and Medicaid …

In Alzheimer disease (AD), which is the most common cause of dementia, the underlying
disease pathology most probably precedes the onset of cognitive symptoms by many years …

The development of prevention therapies for Alzheimer's disease (AD) would greatly benefit
from biomarkers that are sensitive to subtle brain changes occurring prior to the onset of …

Although the diagnosis of dementia is still largely a clinical one, based on history and
disease course, neuroimaging has dramatically increased our ability to accurately diagnose …